Mateos, M., Chari, A., Usmani, S. Z., Goldschmidt, H., Weisel, K., Qi, K., . . . Moreau, P. (2023). Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma. Clinical lymphoma, myeloma & leukemia, 23(5), . https://doi.org/10.1016/j.clml.2023.02.006
Chicago-Zitierstil (17. Ausg.)Mateos, Maria-Victoria, et al. "Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients with Triple-class Exposed Relapsed or Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia 23, no. 5 (2023). https://doi.org/10.1016/j.clml.2023.02.006.
MLA-Zitierstil (9. Ausg.)Mateos, Maria-Victoria, et al. "Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients with Triple-class Exposed Relapsed or Refractory Multiple Myeloma." Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. 5, 2023, https://doi.org/10.1016/j.clml.2023.02.006.